PHARMACIE DU GRAND MAINE : revenue, balance sheet and financial ratios

PHARMACIE DU GRAND MAINE is a French company founded 20 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in ANGERS (49000), this company of category PME shows in 2018 a revenue of 7.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE DU GRAND MAINE (SIREN 483226163)
Indicator 2024 2023 2022 2021 2019 2018 2016
Revenue N/C N/C N/C N/C N/C 7 169 658 € 6 748 566 €
Net income 1 283 761 € 369 007 € 636 528 € 750 067 € 244 538 € -118 243 € 235 637 €
EBITDA N/C N/C N/C N/C N/C 312 735 € 418 763 €
Net margin N/C N/C N/C N/C N/C -1.6% 3.5%

Revenue and income statement

In 2024, PHARMACIE DU GRAND MAINE generates positive net income of 1.3 M€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 236 k€ -> 1.3 M€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

1 283 761 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 85%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 40%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

85.096%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

40.097%

Solvency indicators evolution
PHARMACIE DU GRAND MAINE

Sector positioning

Debt ratio
85.1 2024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average +7 pts over 3 years

In 2024, the debt ratio of PHARMACIE DU GRAND MAINE (85.10) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
40.1% 2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average -8 pts over 3 years

In 2024, the financial autonomy of PHARMACIE DU GRAND MAINE (40.1%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 385.92. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

385.919

Liquidity indicators evolution
PHARMACIE DU GRAND MAINE

Sector positioning

Liquidity ratio
385.92 2024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Excellent +27 pts over 3 years

In 2024, the liquidity ratio of PHARMACIE DU GRAND MAINE (385.92) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE DU GRAND MAINE

Positioning of PHARMACIE DU GRAND MAINE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE DU GRAND MAINE is estimated at 17 922 252 € (range 12 480 773€ - 26 812 715€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
12480k€ 17922k€ 26812k€
17 922 252 € Range: 12 480 773€ - 26 812 715€
NAF 5 année 2024

Valuation method used

Net Income Multiple
1 283 761 € × 14.0x = 17 922 253 €
Range: 12 480 773€ - 26 812 715€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE DU GRAND MAINE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE DU GRAND MAINE

What is the revenue of PHARMACIE DU GRAND MAINE ?

The revenue of PHARMACIE DU GRAND MAINE in 2018 is 7.2 M€.

Is PHARMACIE DU GRAND MAINE profitable?

Yes, PHARMACIE DU GRAND MAINE generated a net profit of 1.3 M€ in 2024.

Where is the headquarters of PHARMACIE DU GRAND MAINE ?

The headquarters of PHARMACIE DU GRAND MAINE is located in ANGERS (49000), in the department Maine-et-Loire.

Where to find the tax return of PHARMACIE DU GRAND MAINE ?

The tax return of PHARMACIE DU GRAND MAINE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE DU GRAND MAINE operate?

PHARMACIE DU GRAND MAINE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.